Brief: Lyra Therapeutics Announces Initiation Of Lyr-210 Pivotal Phase 3 Enlighten Program In Surgically Naïve Chronic Rhinosinusitis Patients

Lyra Therapeutics

24/01/2022 12:17

Jan 24 (Reuters) - Lyra Therapeutics Inc  LYRA.O :
    * LYRA THERAPEUTICS ANNOUNCES INITIATION OF LYR-210 PIVOTAL
PHASE
3 ENLIGHTEN PROGRAM IN SURGICALLY NAÏVE CHRONIC RHINOSINUSITIS
PATIENTS
    * ALSO ANNOUNCES INITIATION OF BEACON CLINICAL STUDY OF
LYR-220 IN
PREVIOUSLY OPERATED CHRONIC RHINOSINUSITIS PATIENTS

Source text for Eikon:  ID:nPn7HWzlka 
Further company coverage:  LYRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))